Urology Medical News about premature ejaculation; paroxetine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Acceptance of and Discontinuation Rate from Paroxetine Treatment in Patients with Lifelong Premature Ejaculation
The Journal of Sexual Medicine, 07/31/09

Salonia A et al. – Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30% of patients who started therapy eventually discontinued it.

Methods

The authors analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE.
The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on–demand treatment or take paroxetine 10 mg daily for 3 months.
The patients were evaluated at 3 and 6 months

Results

Twenty–eight (30.10%) patients decided not to start paroxetine. Fear of using an "antidepressant drug" was the main reason (42.9%) for treatment nonacceptance.
Twenty (30.8%) patients who initiated therapy eventually discontinued it.
Treatment effect below expectations was the main reason of treatment dropout (75%) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15%) and side effects (10%).
Of the patients who continued treatment, 77.8% preferred daily paroxetine, while 22.2% continued as–needed therapy.

<< Previous
Free Radical Theory of Aging: Implications in Male Infertility

Next >>
No evidence for association of the MDM2-309 T/G promoter...

Treatment of Premature Ejaculation in the Asia-Pacific Region: Results from a Phase III Double-blind, Parallel-group Study of Dapoxetine
The Journal of Sexual Medicine, 11/06/09 Relevance Score: 66%

Hormone replacement therapy and successful pregnancy in a patient with premature ovarian failure
Gynecological Endocrinology, 11/16/09 Relevance Score: 46%

Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species
Oncogene, 10/29/09 Relevance Score: 43%

Premature hair greying may predict reduced bone mineral density in Graves' disease
Irish Journal of Medical Science, 10/27/09 Relevance Score: 42%

In vitro fertilisation (IVF) with donor eggs in post-menopausal women: are there differences in pregnancy outcomes in women with premature ovarian failure (POF) compared with women with physiological age-related menopause
Journal of Assisted Reproduction and Genetics, 10/26/09 Relevance Score: 42%